Refocusing on Therapeutic Protein Production in Plants
SREPORT Patricia F. Dimond, Ph.D. In July FDA asked Shire and Protalix BioTherapeutics to submit treatment protocols for their Gaucher disease therapies in the wake of Genzyme’s Allston Landing plant closing. The closing thus...



